Globus Medical reported Q3 2025 revenue of $769.0 million, driven by strength in the U.S. Spine business and contributions from Nevro. GAAP net income more than doubled year-over-year, and adjusted EBITDA and free cash flow reached record levels.

Globus Medical delivered a robust performance in the second quarter of 2025, with worldwide net sales reaching $745.3 million, an 18.4% increase year-over-year. GAAP net income surged by 538.7% to $202.8 million, primarily due to a bargain purchase gain and a tax benefit. Diluted EPS was $1.49, significantly up from $0.23 in the prior year, while non-GAAP diluted EPS also increased to $0.86.

Globus Medical reported a slight decrease in net sales for Q1 2025 compared to the prior year, primarily due to softer Enabling Technology sales and international order timing, offset by strength in the US spine business. The company achieved GAAP net income and positive GAAP and non-GAAP EPS, alongside record Q1 free cash flow and a return to debt-free status.

Globus Medical achieved Q4 2024 revenue of $657.3 million, reflecting a 6.6% increase year-over-year. GAAP net income reached $26.5 million, while non-GAAP net income stood at $117.4 million. Non-GAAP diluted EPS was $0.84, marking a 35.7% improvement from Q4 2023. The company's U.S. sales grew by 6.3%, while international sales increased by 7.7%.

Globus Medical reported a strong third quarter with worldwide net sales of $625.7 million, a 63.1% increase year-over-year. GAAP net income was $51.8 million, and non-GAAP diluted EPS was $0.83. The company raised its full-year revenue guidance to $2.49 to $2.50 billion and non-GAAP EPS guidance to $2.90 to $3.00.

Globus Medical reported a significant increase in worldwide net sales, driven by the addition of NuVasive and increased volume in spine and enabling technology products. GAAP net income decreased due to amortization and restructuring costs, while non-GAAP EPS increased. The company raised its full-year revenue and non-GAAP EPS guidance.

Globus Medical reported a strong first quarter in 2024, marked by a 119.3% increase in worldwide net sales to $606.7 million. The company's GAAP net loss was $7.1 million, while non-GAAP diluted EPS reached $0.72. The results reflect the successful integration of NuVasive and increased sales volume in spine and enabling technology products.

Globus Medical reported a significant increase in worldwide net sales for Q4 2023, driven by the merger with NuVasive and increased volume of spine product sales and enabling technology volume. GAAP net income and EPS decreased, while non-GAAP net income and EPS increased. The company reaffirms its full year 2024 revenue and non-GAAP EPS guidance.

Globus Medical reported a 51.0% increase in worldwide net sales to $383.6 million for Q3 2023, driven by the recent merger with NuVasive. GAAP net income was $1.0 million, with a diluted EPS of $0.01, while non-GAAP diluted EPS reached $0.57. The company has increased its full year revenue guidance to $1.55 billion and reaffirmed its non-GAAP EPS guidance.

Globus Medical reported a record quarter with a revenue of $291.6 million, representing a 10.6% increase compared to the second quarter of 2022. The company's GAAP net income increased by 5.7% year-over-year to $57.7 million, with diluted EPS at $0.57 and non-GAAP diluted EPS at $0.63. The company increased its full year 2023 net sales guidance to $1.125 billion and reaffirmed non-GAAP diluted earnings per share of $2.30.

Globus Medical reported a strong first quarter in 2023, with a 20% increase in worldwide net sales to $276.7 million. GAAP net income increased by 29% to $49.1 million, and non-GAAP diluted EPS rose by 25% to $0.53. The company reaffirmed its full-year 2023 guidance of $1.1 billion in net sales and non-GAAP diluted EPS of $2.30.

Globus Medical reported a record-setting fourth quarter in 2022, achieving record total sales, U.S. Spine sales, and Enabling Technologies sales. Worldwide net sales increased by 9.8% to $274.5 million, with GAAP net income rising by 231.4% to $50.1 million. The company's diluted EPS was $0.49, and non-GAAP diluted EPS was $0.59.

Globus Medical reported a 10.6% increase in worldwide net sales for Q3 2022, reaching $254.1 million. The company's U.S. Spine business grew by 9.0%, while International Spine sales increased by 11.1%. Enabling Technologies also saw significant growth of 19.0%. GAAP net income was $47.4 million, with a diluted EPS of $0.47 and non-GAAP diluted EPS of $0.50.

Globus Medical reported a 5.0% increase in worldwide net sales to $263.6 million in Q2 2022. GAAP net income increased by 31.4% to $54.6 million, with diluted EPS at $0.53 and non-GAAP diluted EPS at $0.56. The Enabling Technologies business grew by 41.7% to $29.4 million.

Globus Medical reported a 1.4% increase in worldwide net sales, reaching $230.5 million. GAAP net income decreased by 16.0% to $38.1 million, with diluted EPS at $0.37 and non-GAAP diluted EPS at $0.42. The company reaffirmed its full-year 2022 guidance of $1.025 billion in net sales and non-GAAP diluted earnings per share of $2.10.

Globus Medical's Q4 2021 results showed a 7.1% increase in worldwide net sales compared to Q4 2020, reaching $250.0 million. GAAP net income decreased by 71.5% to $15.1 million, while non-GAAP diluted EPS was $0.49. The company's Enabling Technology momentum was driven by the clinical superiority of ExcelsiusGPS®, with a record $25 million in revenue.

Globus Medical reported a 6.3% increase in worldwide net sales, reaching $229.7 million. GAAP net income increased by 6.8% to $47.2 million, with a GAAP diluted EPS of $0.45 and a non-GAAP diluted EPS of $0.50. The company reaffirmed its full-year 2021 guidance of $950 million in net sales and non-GAAP diluted earnings per share of $2.00.

Globus Medical reported record revenue of $251 million for Q2 2021, a 69% increase year-over-year. The company's U.S. Spine business grew significantly, and Enabling Technologies revenue nearly quadrupled. GAAP net income and EPS also saw substantial increases.

Globus Medical reported a strong start to 2021 with a 19.3% increase in worldwide net sales, reaching $227.3 million. GAAP net income increased by 74.7% to $45.3 million, and non-GAAP adjusted EBITDA reached $81.0 million, marking 35.2% of net sales.

Globus Medical reported a strong fourth quarter in 2020, with worldwide net sales increasing by 10.3% compared to the same period in 2019. The growth was driven by Enabling Technologies and US Spine. The company's GAAP net income for the quarter was $53.0 million, and non-GAAP diluted EPS was $0.58.

Globus Medical reported a strong third quarter with a 10.1% increase in worldwide net sales to $216.1 million and GAAP net income rising by 15.4% to $44.2 million. Diluted EPS was $0.44, and non-GAAP diluted EPS was $0.49. The U.S. Spine business grew by 17%, offsetting a decline in Enabling Technologies revenue. The company generated $53.2 million in net cash from operating activities and $35.9 million in non-GAAP free cash flow.

Globus Medical reported a decrease in worldwide sales by 23.4% compared to the second quarter of 2019. The company experienced a net loss of $20.8 million, but non-GAAP diluted EPS was $0.07. Despite the challenges, Globus Medical focused on strengthening its business for future growth.

Globus Medical reported a 4.2% increase in worldwide sales, reaching $190.6 million in Q1 2020. Despite the COVID-19 pandemic's estimated $20 million negative impact on sales, the company maintained profitability with a net income of $25.9 million and a non-GAAP adjusted EBITDA of 26.5% of sales. The company launched three new spine products during the quarter and ended the quarter with $657 million in cash, cash equivalents and marketable securities.

Globus Medical reported an 8.0% increase in worldwide sales to $211.7 million for the fourth quarter of 2019. The company's net income increased by 23.9% to $45.5 million, with diluted EPS at $0.44 and non-GAAP diluted EPS at $0.49. The company confirmed full year 2020 sales guidance of $850 million and non-GAAP diluted earnings per share of $1.82.